Shots:
- The UK’s MHRA has approved EURneffy 2mg (adrenaline nasal spray) to treat allergic reactions (anaphylaxis) in children (>30kg); commercially available in the UK by late Q3’25
- In Nov 2024, ARS Pharma granted ALK exclusive rights to commercialize neffy outside the US, incl. EU (as EURneffy), Canada, & select markets in exchange for $145M upfront, ~$320M in regulatory & commercial milestones as well as tiered double-digit royalties in the teens
- ALK launched EURneffy in Germany in late June, with regulatory approvals expected in Canada, Japan (with Alfresa), & Australia (with CSL) by end-2025 & commercial launches in early 2026, while approval in China is anticipated in 2026
Ref: Globenewswire | Image: ARS Pharmaceuticals| Press Release
Related News:- ARS Pharmaceuticals’ neffy 1mg Secures the US FDA’s Approval to Treat Type I Allergic Reactions in Children
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
